Programmed death-1 (PD-1), also know as CD279 is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. Like the clones RMP1-14 and J43 antibodies, the 29F.1A12 antibody has been shown to block the binding of PD-1 to its ligands in vivo.
| Catalog | IV0107 |
| Product Name | InVivoPro Anti-Mouse PD-1(CD279) in vivo antibody, Clone 29F.1A12 |
| Size | 1mg/5mg/25mg/50mg/100mg |
| Isotype | Rat IgG2a |
| Clone | 29F.1A12 |
| Target | PD-1 |
| Other Names | Programmed Death-1, CD279, PD-1 |
| Isotype Control Catalog Code | IV0105 or Rat IgG2a Isotype Control |
| Dilution Buffer | PBS, pH 7.2, contains no stabilizers or preservatives |
| Reactivity | Mouse |
| Host Species | Rat |
| How much antibody to use in vivo | 200-500 μg per mouse; or 10 mg/kg. This range is based off the most recent publication data using the 29F.1A12 clone in vivo. Each investigator should determine their own optimal working dilution for specific applications. |
| Background(ichorbio) | Programmed death-1 (PD-1), also know as CD279 is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is transiently expressed on CD4 and CD8 thymocytes as well as activated T and B lymphocytes and myeloid cells. Like the clones RMP1-14 and J43 antibodies, the 29F.1A12 antibody has been shown to block the binding of PD-1 to its ligands in vivo. |
| Applications | In vivo blocking of PD-1/PD-L signaling, Flow cytometry, Immunohistochemistry(Frozen), Western blot |
| Purification | protein A or G |
| Storage | This antibody is stable for at least 2 months when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at -20°C or -80°C. Avoid repeated freeze thaw cycles. |
| Shipping | 2-8°C with blue ice |
| Concentration | Lot specific, generally ≥ 5.0 mg/ml |
| Shelf Life | 12 months from the date of receipt if stored as recommended |
| Formulation | PBS Buffer, PH 7.2, with no carrier protein, or preservatives. |
| Sterility | 0.2 μM filtered |
| Endotoxin | ≤ 1.0 EU/mg, by the LAL method |
| Purity | 99% |
Zhang, Ying et al. "Enhancing CD8+ T Cell Fatty Acid Catabolism Within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy.",Cancer cell 32.3 (2017): 377-391.e9.
Sheng, Wanqiang et al. "LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade",Cell 174.3 (2018): 549-563.e19.
Pfirschke, Christina et al. "Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy". Immunity vol. 44,2 (2016): 343-54.
© 2021-2025 InvivoCrown Limited. All rights reserved.